Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 2, open-label, multicenter study evaluating adoptive cell therapy (ACT)
with autologous TIL therapy (LN-145) in combination with Anti-PD-L1 inhibitor durvalumab.